Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.34 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5281324 | 1.00 | CYP19A1 (0.46) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL20586240 | 1.00 | CYP19A1 (0.46) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL780036 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28854937 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL18492053 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28986488 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28854935 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL780035 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL13543466 | 0.98 | CYP19A1 (0.47) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL159982 | 0.98 | CYP19A1 (0.47) | CYP19A1EPHX1NAAAL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12479870-B2 | Base-modified cytidine nucleotides for leukemia therapy | MEDIVIR AB (SE) | 2025-11-25 | — | — | US | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12173025-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240309031-A1 | Base-Modified Cytidine Nucleotides for Leukemia Therapy | MEDIVIR AB (SE) | 2024-09-19 | — | — | US | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117379452-A | Substituted nucleosides, nucleotides and analogues thereof | 艾丽奥斯生物制药有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-3160475-B1 | SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS | JANSSEN PHARMACEUTICALS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| CN-1950383-A | Phosphonates, monophosphonamides, bisphosphonates for the treatment of viral diseases | GILEAD SCIENCES INC (US) | 2007-04-18 | — | — | CN | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1716162-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060046981-A1 | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2006-03-02 | — | — | US | disclosed |
| US-20060030545-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050222090-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005066189-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222090-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | CCNY, CCNO, CCNB3 | CYP19A1 711/4885CA2 944/4885GAA 4372/4885 |
| US-20060046981-A1 | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof | HCCS, RCOR3, MSRB3 | CYP19A1 482/4885CA2 1136/4885GAA 4366/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | CYP19A1 3722/4885CA2 3731/4885GAA 4225/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | CYP19A1 4300/4885CA2 4718/4885GAA 1743/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CYP19A1 4300/4885CA2 4718/4885GAA 1743/4885 |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | CYP19A1 626/4885CA2 729/4885GAA 4395/4885 |
| US-12479870-B2 | Base-modified cytidine nucleotides for leukemia therapy | CDA, NUDT1, SLC29A1 | CYP19A1 3255/4885CA2 4368/4885GAA 774/4885 |
| US-20240309031-A1 | Base-Modified Cytidine Nucleotides for Leukemia Therapy | CDA, NUDT1, SLC29A1 | CYP19A1 3255/4885CA2 4368/4885GAA 774/4885 |
| US-12173025-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | CYP19A1 4075/4885CA2 4882/4885GAA 439/4885 |
| US-20060030545-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | CCNY, CCNO, CCNB3 | CYP19A1 621/4885CA2 745/4885GAA 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.